6-80106772-CCTGGCGCGGGG-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_183050.4(BCKDHB):c.93_103del(p.Ala32PhefsTer48) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000126 in 1,589,124 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000013 ( 0 hom. )
Consequence
BCKDHB
NM_183050.4 frameshift
NM_183050.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.48
Genes affected
BCKDHB (HGNC:987): (branched chain keto acid dehydrogenase E1 subunit beta) This gene encodes the E1 beta subunit of branched-chain keto acid dehydrogenase, which is a multienzyme complex associated with the inner membrane of mitochondria. This enzyme complex functions in the catabolism of branched-chain amino acids. Mutations in this gene have been associated with maple syrup urine disease (MSUD), type 1B, a disease characterized by a maple syrup odor to the urine in addition to mental and physical retardation and feeding problems. Alternative splicing at this locus results in multiple transcript variants. [provided by RefSeq, Jan 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant located near the start codon (<100nt), not predicted to undergo nonsense mediated mRNA decay. There are 9 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 6-80106772-CCTGGCGCGGGG-C is Pathogenic according to our data. Variant chr6-80106772-CCTGGCGCGGGG-C is described in ClinVar as [Pathogenic]. Clinvar id is 96618.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BCKDHB | NM_183050.4 | c.93_103del | p.Ala32PhefsTer48 | frameshift_variant | 1/10 | ENST00000320393.9 | NP_898871.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BCKDHB | ENST00000320393.9 | c.93_103del | p.Ala32PhefsTer48 | frameshift_variant | 1/10 | 1 | NM_183050.4 | ENSP00000318351 | P1 | |
BCKDHB | ENST00000356489.9 | c.93_103del | p.Ala32PhefsTer48 | frameshift_variant | 1/11 | 1 | ENSP00000348880 | P1 | ||
BCKDHB | ENST00000369760.8 | c.93_103del | p.Ala32PhefsTer48 | frameshift_variant | 1/6 | 3 | ENSP00000358775 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152168Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152168
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000101 AC: 2AN: 198414Hom.: 0 AF XY: 0.0000183 AC XY: 2AN XY: 109044
GnomAD3 exomes
AF:
AC:
2
AN:
198414
Hom.:
AF XY:
AC XY:
2
AN XY:
109044
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000125 AC: 18AN: 1436956Hom.: 0 AF XY: 0.0000126 AC XY: 9AN XY: 712878
GnomAD4 exome
AF:
AC:
18
AN:
1436956
Hom.:
AF XY:
AC XY:
9
AN XY:
712878
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152168Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74324
GnomAD4 genome
AF:
AC:
2
AN:
152168
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74324
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Maple syrup urine disease Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jan 29, 2024 | The p.Ala32PhefsX48 variant in BCKDHB has been reported in the homozygous and compound heterozygous state in at least 4 individuals (2 homozygotes, 2 compound heterozygote with at least one disease causing allele in BCKDHB) with maple syrup urine disease (MSUD) and segregated with disease in 2 affected relatives from 1 family (Nobukuni 1991 PMID: 2022752, Rodriguez-Pombo 2006 PMID: PMID: 16786533, Tabbouche 2014 PMID: 27896100, Yang 2019 PMID: 31112740). It at least 2 individuals, BCKDH enzyme activity was severely reduced (Nobukuni 1991 PMID: 2022752, Rodriguez-Pombo 2006 PMID: 16786533). The variant was also detected in the heterozygous state in 2 families with MSUD where a second variant was not identified (Parella 1994 PMID: 7707687). This variant has also been reported by other clinical laboratories in ClinVar (Variation ID 96618) and has also been identified in 0.002% (1/41438) of African chromosomes by gnomAD (http://gnomad.broadinstitute.org, v.3.1.2). This variant is a deletion of 11 base pairs and is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at amino acid 32 and leads to a premature termination codon 48 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Biallelic loss of function of the BCKDHB gene is an established disease mechanism in autosomal recessive MSUD. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive MSUD. ACMG/AMP Criteria applied: PVS1, PM3_Moderate, PP1, PM2_Supporting, PP4. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 18, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 27, 2023 | This sequence change creates a premature translational stop signal (p.Ala32Phefs*48) in the BCKDHB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BCKDHB are known to be pathogenic (PMID: 16786533, 22593002). This variant is present in population databases (rs751389206, gnomAD 0.002%). This premature translational stop signal has been observed in individuals with maple syrup urine disease (PMID: 2022752, 31112740). It has also been observed to segregate with disease in related individuals. This variant is also known as c.92_102del11. ClinVar contains an entry for this variant (Variation ID: 96618). For these reasons, this variant has been classified as Pathogenic. - |
Maple syrup urine disease type 1B Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 1991 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 13, 2018 | Variant summary: BCKDHB c.93_103del11 (p.Ala32PhefsX48) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 234612 control chromosomes (gnomAD). c.93_103del11 has been reported in the literature in multiple individuals affected with Maple Syrup Urine Disease (Tabbouche_2014, Rodriguez-Pombo_2006, Parrella_1994, Nobukuni_1991). These data indicate that the variant is very likely to be associated with disease. Experimental evidence evaluating an impact on protein function demonstrated that the variant caused a severe decrease in BCKDH enzyme activity and also, resulted in absence of E1 beta subunit of BCKDH while the E1 alpha subunit of BCKDH was markedly reduced (Nobukuni_1991). A ClinVar submission from a clinical diagnostic laboratory (evaluation after 2014) cites the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 16, 2016 | - - |
Maple syrup urine disease type 1A Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 13, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at